These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 11499562)
1. The key role of the transforming growth factor-beta system in the pathogenesis of diabetic nephropathy. Chen S; Hong SW; Iglesias-de la Cruz MC; Isono M; Casaretto A; Ziyadeh FN Ren Fail; 2001; 23(3-4):471-81. PubMed ID: 11499562 [TBL] [Abstract][Full Text] [Related]
2. Involvement of the transforming growth factor-β system in the pathogenesis of diabetic nephropathy. Ziyadeh FN; Isono M; Chen S Clin Exp Nephrol; 2002 Sep; 6(3):125-9. PubMed ID: 24989950 [TBL] [Abstract][Full Text] [Related]
3. Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Chen S; Jim B; Ziyadeh FN Semin Nephrol; 2003 Nov; 23(6):532-43. PubMed ID: 14631561 [TBL] [Abstract][Full Text] [Related]
4. Potential role of TGF-beta in diabetic nephropathy. Hoffman BB; Sharma K; Ziyadeh FN Miner Electrolyte Metab; 1998; 24(2-3):190-6. PubMed ID: 9525704 [TBL] [Abstract][Full Text] [Related]
5. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Sharma K; Jin Y; Guo J; Ziyadeh FN Diabetes; 1996 Apr; 45(4):522-30. PubMed ID: 8603776 [TBL] [Abstract][Full Text] [Related]
6. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Ziyadeh FN; Hoffman BB; Han DC; Iglesias-De La Cruz MC; Hong SW; Isono M; Chen S; McGowan TA; Sharma K Proc Natl Acad Sci U S A; 2000 Jul; 97(14):8015-20. PubMed ID: 10859350 [TBL] [Abstract][Full Text] [Related]
7. Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy. Wang SN; LaPage J; Hirschberg R Kidney Int; 2000 Mar; 57(3):1002-14. PubMed ID: 10720953 [TBL] [Abstract][Full Text] [Related]
8. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Sharma K; Ziyadeh FN Diabetes; 1995 Oct; 44(10):1139-46. PubMed ID: 7556948 [TBL] [Abstract][Full Text] [Related]
9. Therapy with antisense TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. Han DC; Hoffman BB; Hong SW; Guo J; Ziyadeh FN Am J Physiol Renal Physiol; 2000 Apr; 278(4):F628-34. PubMed ID: 10751224 [TBL] [Abstract][Full Text] [Related]
10. Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator. Ziyadeh FN J Am Soc Nephrol; 2004 Jan; 15 Suppl 1():S55-7. PubMed ID: 14684674 [TBL] [Abstract][Full Text] [Related]
11. Overexpression of upstream stimulatory factor 2 accelerates diabetic kidney injury. Liu S; Shi L; Wang S Am J Physiol Renal Physiol; 2007 Nov; 293(5):F1727-35. PubMed ID: 17881461 [TBL] [Abstract][Full Text] [Related]
12. Prevention of renal apoB retention is protective against diabetic nephropathy: role of TGF-β inhibition. Wilson PG; Thompson JC; Yoder MH; Charnigo R; Tannock LR J Lipid Res; 2017 Dec; 58(12):2264-2274. PubMed ID: 28912302 [TBL] [Abstract][Full Text] [Related]
13. Suppressions of chronic glomerular injuries and TGF-beta 1 production by HGF in attenuation of murine diabetic nephropathy. Mizuno S; Nakamura T Am J Physiol Renal Physiol; 2004 Jan; 286(1):F134-43. PubMed ID: 14519594 [TBL] [Abstract][Full Text] [Related]
14. Role of TGF-beta in pathogenesis of diabetic nephropathy. Pantsulaia T Georgian Med News; 2006 Feb; (131):13-8. PubMed ID: 16575121 [TBL] [Abstract][Full Text] [Related]
15. Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney. Lee EA; Seo JY; Jiang Z; Yu MR; Kwon MK; Ha H; Lee HB Kidney Int; 2005 May; 67(5):1762-71. PubMed ID: 15840023 [TBL] [Abstract][Full Text] [Related]
16. Growth factor ultrafiltration in experimental diabetic nephropathy contributes to interstitial fibrosis. Wang SN; Hirschberg R Am J Physiol Renal Physiol; 2000 Apr; 278(4):F554-60. PubMed ID: 10751215 [TBL] [Abstract][Full Text] [Related]
17. The cyclin kinase inhibitor p21WAF1/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy. Al-Douahji M; Brugarolas J; Brown PA; Stehman-Breen CO; Alpers CE; Shankland SJ Kidney Int; 1999 Nov; 56(5):1691-9. PubMed ID: 10571777 [TBL] [Abstract][Full Text] [Related]
18. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Yamamoto T; Nakamura T; Noble NA; Ruoslahti E; Border WA Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1814-8. PubMed ID: 7680480 [TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor-beta2 antibody attenuates fibrosis in the experimental diabetic rat kidney. Hill C; Flyvbjerg A; Rasch R; Bak M; Logan A J Endocrinol; 2001 Sep; 170(3):647-51. PubMed ID: 11524245 [TBL] [Abstract][Full Text] [Related]
20. Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. Sharma K; Ziyadeh FN Am J Physiol; 1994 Dec; 267(6 Pt 2):F1094-01. PubMed ID: 7810696 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]